The $10 Million Drug That Just Humbled a Pharma Giant
A tiny Minneapolis diagnostics company paid $10 million for a drug Pfizer didn't want. Four years later, it just beat Novartis's Piqray in a head-to-head Phase 3 breast cancer trial, and the implications are enormous.
In 2021, a tiny diagnostics company in Minneapolis bought a drug that Pfizer didn't want anymore. The price tag? A modest $5 million in cash and $5 million in stock. Four years later, that castoff just beat one of Novartis's flagship cancer drugs in a head-to-head Phase 3 trial.
This almost never happens in biotech. A small company taking on a pharma giant's marketed drug in a direct comparison, and winning? It's the equivalent of a minor league team knocking off the Yankees in a best-of-seven series. And yet Celcuity (NASDAQ: CELC) just pulled it off with gedatolisib, a drug that could reshape how doctors treat the most common form of advanced breast cancer.
The Matchup Nobody Expected
The trial is called VIKTORIA-1. Celcuity's gedatolisib, combined with two other cancer drugs (fulvestrant and palbociclib), delivered a statistically significant and clinically meaningful improvement in progression-free survival compared to Novartis's Piqray (alpelisib) plus fulvestrant. Progression-free survival, or PFS, measures how long patients live without their cancer getting worse. It's the gold standard for these kinds of trials.
But the surprises didn't stop there. A secondary analysis tested a simpler combo: gedatolisib plus fulvestrant alone, without the third drug. That regimen also beat Piqray. Two swings, two hits.
Both gedatolisib combos were well tolerated, with no new safety signals. That matters more than you might think, because the drug Celcuity just defeated has a serious toxicity problem.
Piqray's Achilles Heel
Piqray has been on the market since 2019, and oncologists have a love-hate relationship with it. The drug works, but roughly 25% of patients in its pivotal trial had to stop taking it because of side effects. The biggest culprit: severe hyperglycemia, which is a fancy way of saying the drug sends blood sugar levels through the roof. About 65% of patients experience it, and more than a quarter deal with serious cases that require intense monitoring.
Think of Piqray like a sports car with an engine that overheats every other trip. Sure, it's fast, but you spend half your time on the side of the road.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The reason comes down to how each drug works. Piqray is a sniper: it blocks one specific protein called PI3Kα (pronounced "P-I-3-K alpha"), which drives tumor growth in about 40% of HR+/HER2- breast cancers. The problem is that when you block just one protein in a complex signaling chain, the cancer often finds a detour. Other proteins in the same family pick up the slack, and the tumor keeps growing.
A Broader Net, a Better Mousetrap
Gedatolisib takes the opposite approach. Instead of targeting one protein, it blocks all four versions of PI3K plus both forms of mTOR, another key protein downstream in the same pathway. If Piqray is a sniper, gedatolisib is a roadblock across the entire highway.
Scientists call this "vertical blockade" because it shuts down the signaling pathway both upstream and downstream. The cancer can't just reroute around the drug because the drug is everywhere. This broader coverage also means gedatolisib could potentially help patients whose tumors don't carry the PIK3CA mutation, a limitation that restricts Piqray to only a slice of the patient population.
And counterintuitively, hitting more targets doesn't seem to create more side effects. Early thinking suggested the opposite, but gedatolisib's comprehensive blockade may actually allow lower doses to achieve the same effect, keeping toxicity in check.
From Diagnostic Company to Drug Developer
Celcuity's origin story makes this even more remarkable. The company was founded in 2012 by Brian F. Sullivan and Lance G. Laing as a diagnostics firm. Their technology, called CELsignia, analyzes living tumor cells to identify which signaling pathways are driving a patient's cancer. It's clever science, but it wasn't exactly a blockbuster business.
Then came the pivot. In April 2021, Celcuity licensed gedatolisib from Pfizer, which had developed the drug but shelved it. The deal was remarkably cheap: $5 million in cash, $5 million in Celcuity stock, and up to $330 million in milestone payments down the road. Celcuity also secured a $25 million credit line to fund development.
It was a calculated bet. Celcuity's diagnostic platform had given the team deep insight into the PI3K/mTOR pathway, and they believed gedatolisib's broad mechanism could succeed where narrower drugs had stumbled. The total upfront cost of $10 million is pocket change in an industry where a single Phase 3 trial can cost hundreds of millions.
The Competitive Battlefield
Gedatolisib isn't entering a vacuum. The PI3K pathway space in breast cancer is getting crowded, and Celcuity will need to fight for market share against several well-funded competitors.
Capivasertib (Truqap), an AKT inhibitor from AstraZeneca, won FDA approval in November 2023. It has a broader label than Piqray because it works in patients with PIK3CA, AKT1, or PTEN alterations, not just PIK3CA mutations. Then there's inavolisib (Itovebi) from Roche, another PI3Kα inhibitor that reported positive Phase 3 results in early 2025 and is angling for the same patients.
Beyond the PI3K pathway, drugs like Enhertu and Datroway (both approved in January 2025 for certain HR+/HER2- patients) are expanding the overall treatment toolkit. The second-line treatment landscape after CDK4/6 inhibitor failure remains fragmented, with patients cycling through various endocrine combinations, chemotherapy, and targeted therapies.
That fragmentation is actually good news for Celcuity. There's no clear standard of care after first-line treatment fails, which means a drug that wins a head-to-head trial against an established competitor has a real shot at claiming the throne.
The Road to FDA Approval
Celcuity already has one foot in the door at the FDA. Data from VIKTORIA-1's PIK3CA wild-type cohort (patients without the mutation) supported a Priority Review NDA with a PDUFA goal date of July 17, 2026. That's the deadline by which the FDA aims to make a decision.
The new mutant-cohort data will support a supplemental filing, potentially expanding gedatolisib's label to cover PIK3CA-mutant patients as well. If both get approved, gedatolisib would be one of the rare drugs that works across a broad patient population regardless of mutation status.
Detailed results will be unveiled at the ASCO Annual Meeting on June 2, 2026, in a late-breaking oral presentation (the most prestigious slot at the world's biggest cancer conference). That's when we'll finally see the actual PFS numbers and hazard ratios that Celcuity has kept under wraps so far.
Wall Street's Muted Reaction
You'd think a small biotech beating a Novartis drug would send the stock soaring. Instead, Celcuity shares rose just 1.97% on the news. Much of the good news was already baked in.
Analysts maintain a "Strong Buy" consensus, and the sentiment around the announcement was overwhelmingly positive. But the real catalysts still lie ahead: the ASCO presentation in June, the PDUFA date in July, and the supplemental filing for PIK3CA-mutant patients. Each milestone is a chance for the stock to re-rate higher, or to stumble if the detailed data disappoints.
Why This Matters Beyond the Stock Price
HR+/HER2- breast cancer is the most common subtype, accounting for roughly 70% of all breast cancers. PIK3CA mutations show up in about 40% of those cases. We're talking about a massive patient population with limited second-line options and real, daily struggles with drug side effects.
The existing PI3K inhibitors work, but they come with a heavy toll. If gedatolisib can deliver better efficacy and better tolerability (both of which the topline data suggest), it could fundamentally change how oncologists sequence treatments after CDK4/6 inhibitors fail.
Four years ago, Celcuity was a diagnostics company with a $10 million Pfizer hand-me-down. Now it's sitting on a potential best-in-class breast cancer drug with a clear path to approval. In biotech, the underdog stories are rare. This one might actually have a happy ending.
Clinical & Regulatory
4 min read
The White House Just Went Pro-Psychedelics. Nobody Saw It Coming.
The Trump administration went from blocking a psychedelics company's FDA voucher to signing an executive order calling these drugs "life-saving," all in about 60 days. Three companies just got golden tickets that could slash their FDA review from 10 months to under two.
